DCF Advisers’s AbbVie ABBV Stock Holding History

DCF Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,500	Closed	-$812K	–	94
2021 Q1	$812K	Buy	+7,500	New	+$802K	0.35%	57

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCF Advisers's ABBV Position: Q1 2026 in Review

DCF Advisers held its AbbVie (ABBV) position steady in Q1 2026 at 10,750 shares worth $2.34M. The position accounts for 0.62% of the portfolio, ranked #38.

DCF Advisers first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $14.4M in Q1 2022. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

DCF Advisers held 10,750 shares of AbbVie worth $2.34M as of Q1 2026.
DCF Advisers left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.62% of DCF Advisers's portfolio in Q1 2026, its #38 holding.
DCF Advisers first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
DCF Advisers's AbbVie position peaked at $14.4M in Q1 2022.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.